Signaling by ERBB2 KD Mutants (Q100166260)

An instance of the biological pathway in Homo sapiens with Reactome ID (R-HSA-9664565)

Language	Label	Description	Also known as
English	Signaling by ERBB2 KD Mutants	An instance of the biological pathway in Homo sapiens with Reactome ID (R-HSA-9664565)

Statements

instance of

1 reference

8 July 2022

Signaling by ERBB2 in Cancer

1 reference

8 July 2022

1 reference

8 July 2022

https://identifiers.org/reactome:R-HSA-9664565

1 reference

8 July 2022

ERBB2 KD mutants heterodimerize

1 reference

8 July 2022

ERBB2 KD mutants trans-autophosphorylate

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K

1 reference

8 July 2022

PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 converts PIP2 to PIP3

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:GAB1

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K

1 reference

8 July 2022

PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR converts PIP2 to PIP3

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants bind SHC1

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1

1 reference

8 July 2022

RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1

1 reference

8 July 2022

RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind PLCG1

1 reference

8 July 2022

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR phosphorylate PLCG1

1 reference

8 July 2022

ERBB2 KD mutants bind TKIs

1 reference

8 July 2022

ERBB2 KD mutants bind trastuzumab

1 reference

8 July 2022

Combined blockade of activating mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer

1 reference

8 July 2022

Activating HER2 mutations in HER2 gene amplification negative breast cancer

1 reference

8 July 2022

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.

1 reference

8 July 2022

Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface

1 reference

8 July 2022

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer

1 reference

8 July 2022

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

1 reference

8 July 2022

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation

1 reference

8 July 2022

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.

1 reference

8 July 2022

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies

1 reference

8 July 2022

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

1 reference

8 July 2022

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

1 reference

8 July 2022

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

1 reference

8 July 2022

Integrated genomic analyses of ovarian carcinoma

1 reference

8 July 2022

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

1 reference

8 July 2022

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

1 reference

8 July 2022

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

1 reference

8 July 2022

Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity

1 reference

8 July 2022

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

1 reference

8 July 2022

Identifiers

1 reference

8 July 2022

Signaling by ERBB2 KD Mutants (Q100166260)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Signaling by ERBB2 KD Mutants (Q100166260)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search